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This study evaluated how change in posttraumatic stress disorder (PTSD) symptoms 
was associated with residualized change in comorbid personality disorder (PD) 
features and vice versa over the course of 5–10 years. The sample was comprised of 
79 female rape survivors who met criteria for PTSD and who were a part of a larger 
study examining the effects of trauma-focused therapy. PTSD was assessed with the 
fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) 
version of the Clinician-Administered PTSD Scale [CAPS-IV (1)] and PD features were 
assessed with the DSM-IV dimensional PD scales on the Schedule for Non-adaptive 
and Adaptive Personality [SNAP (2)]. PTSD symptom severity and PD features were 
assessed at baseline and between 5 and 10 years after completing treatment. Multiple 
regression analyses revealed that PTSD symptom change was related to residualized 
change in PD severity for paranoid, schizotypal, antisocial, borderline, avoidant, and 
dependent PD (βs ranged from −0.23 to −0.33; all ps < 0.05). In addition, for borderline 
and antisocial PDs, longitudinal stability of the PD was attenuated among those with 
greater PTSD symptom improvement (i.e., the relationship between these PDs over time 
was altered as a function of PTSD symptom change; βs ranged from −0.27 to −0.29; 
all ps < 0.05). Similarly, change in severity of paranoid, schizotypal, antisocial, avoidant, 
and obsessive–compulsive (OC) PD was associated with residualized change in PTSD 
symptoms (βs ranged from −0.32 to −0.41; all ps < 0.05), and the longitudinal stability 
of PTSD was attenuated as a product of change in OC PD (β = −0.27; p < 0.02). These 
findings suggest that these two sets of disorders may impact one another substantially, 
altering the course of even chronic, characterological conditions. This carries important 
clinical implications for the treatment of both PTSD and PDs.
Keywords: PTsD, personality disorders, trauma, longitudinal, rape
inTrODUcTiOn
Posttraumatic stress disorder (PTSD) is highly comorbid with a range of other mental health 
disorders. In fact, Brown et al. (3) found that of the anxiety and mood disorders, PTSD had the 
highest prevalence and most diverse pattern of comorbid psychopathology. Similarly, in the National 
Comorbidity Study, Kessler et al. (4) found that PTSD was associated with increased odds of being 
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diagnosed with a mood disorder, an anxiety disorder, alcohol/
drug abuse or dependence, and conduct disorder (4). More recent 
research has identified a link between psychosis and PTSD, with 
estimates suggesting that the prevalence of PTSD in people with 
psychotic disorders ranges from 12 to 29% (5, 6).
Posttraumatic stress disorder is also highly comorbid with 
many personality disorders (PDs). In a national epidemiologi-
cal survey, Pietrzak et al. (7) found that 50% of individuals with 
PTSD also met criteria for at least one PD. Further, in a sample of 
male combat Veterans with PTSD, Dunn and her colleagues (8) 
found that more than 45% met criteria for at least one PD, and 
more than 16% met criteria for two or more PDs.
Traditionally, PDs have been conceptualized as stable and 
unresponsive to treatment. According to the fourth edition 
of the Diagnostic and Statistical Manual of Mental Disorders 
[DSM-IV (9); the version of the manual most relevant to this 
manuscript, although this definition has been preserved in 
DSM-5], a PD is “an enduring pattern of inner experience and 
behavior that … is pervasive and inflexible … is stable over time, 
and leads to distress or impairment,” [p. 629; italics added (9)]. 
Recent studies have offered greater optimism about the course 
of PDs, suggesting that PD features can improve both over 
time and in response to treatment (10, 11). Consistent with 
this, in a study designed to examine the association between 
PTSD treatment and change in PDs, Markowitz and his col-
leagues (12) found that after a short course of trauma-focused 
therapy, 43% of participants lost their PD diagnosis by the end 
of treatment. There was no association between PTSD change 
and PD change explicitly, which they hypothesized could be 
due to a limited sample size (only 35 participants had a PD 
at baseline), the range of PDs excluded (i.e., participants who 
met criteria for borderline, antisocial, schizoid, and schizotypal 
PD at baseline), and/or the broad level of PD improvement. 
However, they did find that 56% of patients with PTSD and a 
comorbid PD who responded to the intervention [i.e., ≥30% 
Clinician-Administered PTSD Scale (CAPS) improvement] 
lost their PD diagnosis by the 26-week follow-up. Because of 
the small sample size and range of PDs excluded, it is unclear 
whether Markowitz et  al.’s results generalize to the full range 
of PDs or if differential patterns of co-occurring change might 
emerge across specific PDs.
In addition to the limited body of research focused on how 
PTSD change affects PDs over time, a similarly small number of 
studies have examined the comparable question regarding how 
PDs might affect PTSD change over time. The studies that do 
exist have focused on the predictive value of PDs at baseline on 
PTSD change; in general, they have suggested that PDs do not 
interfere with changes in PTSD [e.g., Ref. (13, 14)]. However, 
these studies have not tended to evaluate how PD change (as 
opposed to baseline PD features) may relate to PTSD change 
over time.
Despite the lack of empirical attention, there is reason to 
suspect co-occurring change in PTSD and PDs. Research has sug-
gested that PTSD and PDs may share an underlying vulnerability 
that may contribute to both disorders. Specifically, trait negative 
emotionality (NEM; reflecting a tendency toward negative affect 
and generalized distress that is rooted in temperament) has 
been identified as the primary risk factor for the development of 
PTSD and its comorbidities [e.g., Ref. (15–17)], and may underlie 
a range of posttraumatic psychopathology (18), including PDs 
(19). Therefore, it is possible that co-occurring symptom reduc-
tions in PTSD and PD could arise from decreases in this shared 
underlying vulnerability. It is also possible that in response to 
trauma, repeated victimization, and avoidant behavior, people 
develop overgeneralized patterns of behavior and thinking that is 
diagnosed as a PD (20), but may more accurately reflect trauma-
related psychopathology.
The purpose of this study was to examine how changes in 
PTSD and PD severity covary over time. To investigate this 
question, we conducted secondary data analyses on existing 
data from a treatment trial conducted by Resick et  al. (21), 
comparing cognitive processing therapy (CPT) and prolonged 
exposure (PE) for the treatment of chronic PTSD in female rape 
survivors. We examined the baseline data from the trial as well 
as the long-term follow-up (LTFU) data collected 5–10  years 
after treatment (22). Previously published research from this 
trial found that PTSD symptoms decreased significantly as the 
result of trauma-focused therapy (21), and therefore, this dataset 
provided an excellent opportunity to examine the covariation 
of change in PTSD severity and PDs. We hypothesized that 
PD features would decrease in severity (as operationalized by 
a residualized change score variable, see below) among those 
with the greatest PTSD change (e.g., co-occurring symptom 
amelioration), and that the longitudinal stability of PD features 
would be attenuated in individuals who experienced the greatest 
amount of PTSD symptom improvement. That is, PD features, 
which are traditionally thought to be stable and intractable (9), 
may become less stable given PTSD symptom improvement. 
With respect to the related question of how PD changes are 
associated with PTSD changes, we similarly hypothesized that 
reductions in PD severity would predict decreases in PTSD 
severity (again operationalized as a residualized change score) 
and that the longitudinal stability of PTSD severity (23, 24) 
would be attenuated in individuals who experienced the greatest 
amount of PD symptom improvement. We did not make specific 
hypotheses about differential patterns of change as a function 
of each specific PD, but generally thought that PDs with greater 
saturation with underlying NEM would evidence the greatest 
co-occurring change.
ParTiciPanTs anD MeThODs
Participants
Participants had experienced at least one completed rape and 
met full DSM-IV PTSD criteria. Treatment trial exclusion 
criteria included current substance dependence, illiteracy, 
suicidal/homicidal intent or parasuicidal behavior, psychosis, 
involvement in an abusive relationship, and being stalked. 
There were 171 participants in the original intent-to-treat 
sample. Of these, 79 participants had complete data on all vari-
ables of interest for this study. Participants who were excluded 
from the current study did not differ from those included on 
age (t =  0.33; p >  0.05), education (t =  0.32; p >  0.05), race 
(χ2 = 3.05; p > 0.05), or baseline PTSD severity or PD scores 
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(all ts < 1.86; all ps > 0.05). The 79 participants ranged in age 
from 18 to 55 years (M = 31.7; SD = 9.6); 70% self-reported as 
Caucasian, 27% African-American, and 3% other. Participants 
reported 10–24 years of education (M = 14.3; SD = 2.3). Of the 
79 included participants, 38 were randomly assigned to receive 
CPT and 41 to PE. This was a highly traumatized sample. In 
addition to experiencing at least one completed rape, the 
prevalence of additional trauma exposure in the sample was as 
follows: 39% (n =  31) reported childhood sexual abuse; 24% 
(n = 29) witnessed or learned of a criminal or vehicular homi-
cide of a close friend or family member; 15% (n = 12) reported 
being the victim of attempted murder; 18% (n = 14) reported 
being robbed; 21% (n =  17) reported being kidnapped; 19% 
(n =  15) reported serious physical assault; and 53% (n =  42) 
reported experiencing at least one other rape (in addition to 
the index event).
Procedure
Data for the current study were collected as part of a larger 
randomized controlled trial (21). All participants received either 
CPT or PE. Approximately 5–10  years later (M =  6.03  years, 
SD =  0.93  years), participants were re-contacted and asked to 
complete the same measures as at baseline. Institutional Review 
Board approval was secured for all phases of the study.
Measures
The Clinician-Administered PTSD Scale for DSM-IV [CAPS-IV 
(1)] is a reliable and valid structured diagnostic interview that 
assesses DSM-IV PTSD severity and diagnosis. For each symp-
tom, a clinician rates two dimensions, frequency and intensity, 
on separate five-point scales; these scales can be combined across 
items to form a total PTSD severity score, which was used in this 
study. Interrater reliability for total PTSD symptom severity was 
0.97 for baseline and 0.94 for LTFU.
The Schedule for Non-adaptive and Adaptive Personality 
[SNAP (2)] is a personality inventory comprised of validity scales, 
temperament and trait scales, and 13 PD scales with dichotomous 
(diagnostic) and dimensional scoring options. Ten scales reflect 
DSM-IV PD criteria. The dimensional scores for these 10 PD 
scales were used in analyses because prior work suggests that they 
are internally consistent and relate well to interview-based PD 
assessments; the dichotomous scores show weaker associations 
with these assessments (2, 25). Further, the long-term rank-order 
stability (i.e., correlation) of the dimensional scores is strong 
[mean 2-year PD severity correlation =  0.69 (26)], even with 
declining group mean levels over time, suggesting that these 
scales tend to be stable and reliable over time. We also chose to 
focus on the dimensional scores rather than the diagnostic scores 
because this approach is more aligned with research supporting 
the dimensionality of PDs (25, 27, 28).
At the LTFU visit, we assessed additional treatment completed 
after the trial with a single yes/no question: “Have you received 
more therapy since you completed our program?”
Data analysis
First, we examined group mean changes for PDs and PTSD by 
comparing baseline and LTFU SNAP and CAPS scores using 
paired-sample t-tests. In addition, we conducted correlational 
analyses to examine how PD feature scores at each time point 
were associated with each other as well as with the CAPS severity 
scores at both time points.
To test our first hypothesis, that individuals who experienced 
improvement in PTSD symptoms also demonstrated reductions 
in PD features, we ran 10 hierarchical multiple regression analy-
ses (1 for each PD). Each regression had five steps with the LTFU 
PD score as the dependent variable and the following variables 
entered into each step of the equation as predictors: (1) SNAP 
baseline PD score; (2) treatment completer status (0 = did not 
complete treatment; 1 = completed treatment); (3) CAPS change 
score (baseline-LTFU); (4) interaction of baseline PD × CAPS 
change; and (5) additional treatment received after study com-
pletion (0 =  no additional treatment received; 1 =  additional 
treatment received). In these analyses, the dependent variable is 
an index of residualized change in each PD. Residualized change 
scores (29, 30) are common in the research literature [e.g., Ref. 
(31–34)]. They reflect residual variance in the dependent vari-
able that is not predicted by the same variable measured at an 
earlier time point. In other words, when there is either positive 
or negative residual variance in the dependent variable, this 
reflects increased or decreased level of the dependent variable, 
respectively.
Step 1 allowed for evaluation of the longitudinal stability 
of the PD features and controlled for baseline PD scores in 
subsequent steps, with a positive sign indicating that higher 
PD feature scores at baseline were associated with higher 
PD feature scores at LTFU. Step 2 controlled for the effect 
of treatment completion to separate variance associated with 
therapy completion from that associated with symptom change. 
Treatment completion was entered at Step 2 because we wanted 
to first account for variance attributable to completion of the 
study and then determine the extent to which PTSD symp-
tom change accounted for additional variance beyond that 
attributable to simply completing the study. For this step, a 
negative sign indicated that completer status was associated 
with decreases in PD at LTFU. Step 3 tested the main effect 
of PTSD change on residualized change in LTFU PD features. 
In other words, this step examined if greater PTSD symptom 
improvement was associated with less PD severity at LTFU 
when baseline levels of the PD were held constant at the sample 
mean. For this step, a negative sign indicated that more PTSD 
symptom reduction was associated with lower LTFU PD feature 
scores. Step 4 tested if PTSD change moderated the relation-
ship between baseline and LTFU PD scores. That is, this step 
examined if the longitudinal stability of PDs was attenuated 
among those with the greatest PTSD symptom improvement. 
This step effectively begins to look at subgroups within the 
sample by examining if there are different slopes for the 
longitudinal PD association as a function of degree of PTSD 
change. A negative sign for this step suggested that the stability 
of the LTFU PD was attenuated as a product of greater PTSD 
reduction. Step 5 tested whether additional treatment received 
after the treatment phase of the study added additional variance 
to the model. This was entered as the last step to reflect the 
temporal ordering of the variables since this variable captured 
TaBle 1 | Baseline and lTFU posttraumatic stress disorder symptom 
severity scores and personality disorder feature scores.
Variable Time point t-Test 
t (df)
Baseline lTFU
(n = 79)
M sD M sD
caPs 77.15 19.61 26.33 24.31 17.40 (78)**
snaP
Paranoid 13.77 4.89 8.79 5.59 9.18 (78)**
Schizoid 7.10 3.17 5.70 3.40 4.26 (78)**
Schizotypal 12.19 4.29 8.32 4.94 7.46 (78)**
Antisocial 8.97 5.44 7.57 5.25 3.04 (78)**
Borderline 11.81 4.85 8.24 5.83 6.06 (78)**
Histrionic 8.94 4.19 7.67 3.69 3.43 (78)**
Narcissistic 9.30 3.92 7.27 3.67 5.18 (78)**
Avoidant 11.11 3.76 8.33 4.48 5.86 (78)**
Dependent 9.89 4.68 6.35 4.16 7.81 (78)**
OC 12.85 3.23 10.81 3.74 5.62 (78)**
LTFU, long-term follow-up; CAPS, Clinician-Administered PTSD Scale; SNAP, Schedule 
for Non-adaptive and Adaptive Personality; OC, obsessive–compulsive.
**p < 0.01.
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variance from the end of the treatment trial to the LTFU. For 
this step, a positive sign indicated that individuals engaged 
in additional treatment after the trial phase of the study had 
higher LTFU PD feature scores.
We followed the same analytic approach to test our second and 
complementary hypothesis, that individuals who demonstrate a 
reduction in PD features also demonstrate decreases in PTSD 
symptoms (as indexed by residualized change scores), in 10 
hierarchical multiple regression analyses (one for each PD). As 
before, each regression had five steps: (1) CAPS baseline sever-
ity score; (2) treatment completer status; (3) PD change score 
(baseline-LTFU); (4) interaction of baseline CAPS × PD change; 
and (5) additional treatment received after study completion. 
Interpretation of these regression coefficients mirrored those 
described above, with the exception being that these related to 
LTFU PTSD scores (not PDs).
For both sets of analyses, we used Holm (35) correction for the 
overall F-test to protect against type I error given the 10 regres-
sions (one for each PD) conducted in each set of analyses. Effect 
size was evaluated by calculating Cohen’s (36) f 2 (0.02 = small, 
0.15 =  medium, 0.35 =  large). Prior to conducting hypothesis 
testing, we centered all predictors included in interaction terms to 
avoid concerns related to multicollinearity and inflated standard-
ized effect size estimates.
resUlTs
Descriptive statistics for the CAPS and PD scales, and t-tests 
examining group mean changes over time, are presented in 
Table 1. Correlational analyses are presented in Table 2. Before 
proceeding with our planned analyses, we explored the potential 
effect of treatment type. We compared means for the two treat-
ments at baseline and LTFU; participants who received CPT 
versus PE did not differ on baseline (all ts < 1.90; all ps > 0.15) 
or LTFU (all ts < 1.70; all ps > 0.05) CAPS or PD scores in these 
79  subjects. Therefore, we collapsed the data across treatment 
type for all subsequent analyses.
Predicting lTFU PDs
Next, we evaluated if change in PTSD severity was associated 
with residualized change in PD features in 10 separate regres-
sions. For all regressions, the overall F-test met the adjusted 
Holm criterion for statistical significance (all ps < 0.005). In each 
equation, baseline PD significantly predicted LTFU PD with 
large effect sizes (all (f 2 > 0.30; Table 3), indicating substantial 
stability. Completion of treatment added a small amount of 
incremental variance to the prediction of residualized change in 
LTFU paranoid (f 2 = 0.06), schizotypal (f 2 = 0.05), and obses-
sive–compulsive (OC) PD (f 2 =  0.04; Table 3), suggesting that 
completing a course of trauma-focused therapy was associated 
with decreased PD features at LTFU. Change in CAPS scores 
added significant incremental variance to the prediction of LTFU 
paranoid (f 2 = 0.09), schizotypal (f 2 = 0.12), antisocial (f2 = 0.05), 
borderline (f 2 = 0.06), avoidant (f 2 = 0.09), and dependent PD 
(f2 = 0.09; Table 3), suggesting that PTSD symptom reductions 
were associated with residualized change (reductions) in these 
PDs (and similarly, PTSD symptom increases were associated 
with PD increases).
The interaction between baseline PD features and CAPS 
change added incremental variance in Step 4 to the prediction 
of LTFU antisocial (f 2 =  0.09) and borderline PD (f 2 =  0.07; 
Table 3). To depict these interactions, we plotted the association 
between PD at baseline and LTFU as a function of change in 
CAPS. Degree of CAPS change was defined by a median split 
on the CAPS difference score for the purposes of the figures 
(Figures  1 and 2). These figures show that participants with 
greater decreases on the CAPS evidenced sharper declines in PD 
features over time (i.e., the substantial stability of PD features 
evident from the results of Step 1 of the equation was attenuated 
for individuals who achieved greater PTSD improvement). These 
figures also show the stability (i.e., slope) of borderline and anti-
social PD change as a function of CAPS change in comparison 
to the average stability of these PDs over time (shown in red). 
Results indicated that additional treatment after completion of 
the study treatment protocol resulted in small but significant 
increases in variance explained in LTFU schizotypal (f 2 = 0.04) 
and borderline PD (f 2 =  0.03; Table 3), such that participants 
who sought additional treatment had higher LTFU PD scores 
than those who did not.
In summary, this set of analyses revealed that greater PTSD 
symptom improvement was associated with greater residualized 
change (symptom improvement) in paranoid, schizotypal, anti-
social, borderline, avoidant, and dependent PDs. Further, results 
revealed that for borderline and antisocial PD, the stability of 
the PD was not uniform across subjects, but rather, there were 
different slopes for the longitudinal PD association that differed 
by the degree of PTSD change.
Predicting lTFU PTsD
We next evaluated if change in PD features was associated with 
residualized change (e.g., improvements) in PTSD severity in 
TaBle 2 | correlations between baseline and lTFU posttraumatic stress disorder symptom severity scores and personality disorder scores (n = 79).
Variable caPs-iV Paranoid schizoid schizotypal antisocial Borderline histrionic narcissistic avoidant Dependent Oc
CAPS-IV 0.37** 0.22 0.42** 0.25* 0.28* 0.15 0.22 0.28* 0.30** 0.19
Paranoid 0.14 0.62** 0.87** 0.51** 0.70** 0.15 0.58** 0.72** 0.44** 0.59**
Schizoid −0.10 0.22 0.69** 0.27* 0.37* −0.34** 0.18 0.76** 0.05 0.35*
Schizotypal 0.13 0.68** 0.47** 0.52** 0.68** 0.08 0.55** 0.74** 0.42** 0.53**
Antisocial 0.15 0.29** −0.04 0.42** 0.72** 0.50** 0.58** 0.25* 0.51** 0.24*
Borderline 0.36** 0.42** 0.01 0.48** 0.64** 0.35** 0.57** 0.53** 0.66** 0.49**
Histrionic 0.26* 0.16 −0.46** 0.06 0.51** 0.46** 0.55** −0.24* 0.37** 0.15
Narcissistic 0.01 0.45** −0.11 0.43** 0.58** 0.46** 0.60** 0.21 0.36** 0.52**
Avoidant 0.09 0.47** 0.70** 0.49** −0.04 0.22* −0.44** −0.10 0.33** 0.48**
Dependent 0.35** 0.12 −0.32** 0.08 0.17 0.49** 0.39** 0.05 0.02 0.21
OC 0.10 0.53** 0.26** 0.34** 0.03 0.27* −0.06 0.21 0.52** −0.05
The lower triangle reflects correlations from baseline assessments and the upper triangle reflects correlations from the LTFU assessments. LTFU, long-term follow-up; OC, 
obsessive–compulsive; CAPS-IV, Clinician-Administered PTSD Scale for DSM-IV.
*p < 0.05.
**p < 0.001.
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10 separate regressions.1 Five of the overall F-tests did not meet 
the Holm criterion for statistical significance and were therefore 
not interpreted.2 In each of the five equations that were inter-
pretable (i.e., those involving paranoid, schizotypal, antisocial, 
avoidant, and OC PD), baseline CAPS significantly predicted 
LTFU CAPS (f2 =  0.06; Table  4). By contrast, completion of 
treatment, entered in Step 2, did not add significant incremental 
value to any of the models (all ps > 0.05). However, changes in 
all five of these PDs (all f2 > 0.10) added significant incremental 
variance to the prediction of LTFU CAPS. These results suggest 
that in these five analyses, PD change covaried with residualized 
PTSD change.
The interaction between baseline CAPS and change in OC PD 
features (f2 = 0.07) added significant incremental variance to the 
prediction of LTFU CAPS (Table 4). To depict this interaction, 
we plotted the association between baseline and LTFU PTSD 
symptom severity as a function of change in OC PD. Degree of 
PD change was defined for the purposes of the figure, by a median 
split on the OC PD difference score (Figure 3). The figure shows 
that individuals with greater decreases on OC PD evidenced 
greater residualized change (e.g., sharper declines) in PTSD 
severity over time. Specifically, the association between baseline 
and LTFU CAPS was attenuated for those who demonstrated 
the greatest OC PD improvement. The differential strength of 
association between PTSD at baseline and LTFU as a function of 
OC PD change can be viewed in contrast to the average stability 
of PTSD over time (shown by the red line in Figure 3). Results 
from Step 5 of the equations indicated that receiving additional 
treatment after completion of the study treatment protocol did 
1 An initial examination of the data suggested the existence of a number of potential 
outliers. We tested for multivariate outliers using leverage tests and found that five 
participants had leverage values that were more than 2 SDs above the mean. These 
five participants were therefore excluded from all subsequent analyses.
2 For these analyses, the most significant test needed to surpass adjusted p < 0.005 
(0.05/10) and the least significant test needed to surpass p < 0.05 (0.05/1). Overall 
model p-values for histrionic, narcissistic, dependent, borderline, and schizoid PDs 
did not meet these thresholds, though results are reported in Table 4 for complete-
ness. For the remaining five analyses, the overall model surpassed the intervening 
adjusted p-value thresholds (all ps < 0.004).
not improve prediction of LTFU CAPS severity in any of the 
models (Table 4).
In summary, this set of analyses revealed that decreases in 
features of paranoid, schizotypal, antisocial, avoidant, and OC 
PD were associated with greater residualized change (decreased 
severity) in PTSD. Beyond this, the average stability of PTSD 
symptoms over time was altered as a function of the degree of 
change in OC PD features, with subjects who showed greater 
decreases in this PD also demonstrating reduced PTSD stability 
over time.
DiscUssiOn
To our knowledge, the current study is the first to examine 
associations between PTSD and PD symptom change over the 
long-term and to do so for all 10 DSM-IV PDs. To explore these 
associations, we conducted two sets of analyses. Our first set of 
analyses examined how change in PTSD severity was associated 
with residualized change in PD severity. We found that change 
in PTSD severity correlated with PD scores at LTFU for six of 
the PDs (paranoid, schizotypal, antisocial, borderline, avoidant, 
and dependent), even after controlling for baseline levels of these 
PDs. This association implies that PTSD change was associated 
with residualized change in these six PDs such that improvements 
in PTSD covaried with reductions in each PD. This extends the 
work of Markowitz et al. (12) in that our results suggest that PTSD 
change is associated with PD change, and that participation in 
trauma-focused therapy is associated with decreases across a 
range of PDs (i.e., lower scores than what would be predicted 
based on baseline level of PD). These findings are particularly 
important because the treatments given were brief with only 
13 hours of therapist contact in total conducted twice a week.
Interestingly, five of the six PDs (paranoid, schizotypal, 
antisocial, borderline, and dependent) that were significantly 
associated with change in PTSD severity in this study have been 
previously shown to be strongly related to trait NEM (19). The 
sixth PD, avoidant PD, is thought to have equivalent associations 
with NEM and trait positive emotionality [PEM; i.e., a tendency 
towards positive affect and social closeness (25)]. This suggests 
TaBle 3 | hierarchical linear regression analyses predicting change in PD features as a function of change in posttraumatic stress disorder.
Predictor
PD step 1 
Baseline PD
step 2 
Tx completer
step 3 
caPs Δ
step 4  
Baseline PD × caPs Δ
step 5 
additional Tx
Paranoid
ΔR2 0.34** 0.06** 0.09** 0.01 0.01
β 0.58** −0.24** −0.29** −0.08 0.19
B (SE) 0.67 (0.11) −2.83 (1.06) −0.06 (0.02) −0.00 (0.00) 1.29 (0.98)
(CI) (0.46–0.88) (−4.94 to −0.72) (−0.10 to −0.03) (−0.01 to 0.00) (−0.66 to 3.23)
schizoid
ΔR2 0.36** 0.02 0.03 0.01 0.00
β 0.60** −0.15 −0.16 −0.11 0.05
B (SE) 0.65 (0.10) −1.06 (0.66) −0.02 (0.01) −0.00 (0.00) 0.36 (0.63)
(CI) (0.45–0.84) (−2.36 to 0.25) (−0.04 to 0.00) (−0.01 to 0.00) (−0.90 to 1.62)
schizotypal
ΔR2 0.26** 0.04* 0.11** 0.02 0.04*
β 0.51** −0.22* −0.33** −0.14 0.20*
B (SE) 0.59 (0.11) −2.25 (1.04) −0.06 (0.02) −0.01 (0.00) 2.04 (0.90)
(CI) (0.36–0.81) (−4.31 to −0.19) (−0.10 to −0.03) (−0.02 to 0.00) (0.25–3.83)
antisocial
ΔR2 0.50** 0.01 0.05** 0.08** 0.01
β 0.71** −0.12 −0.23** −0.29** 0.08
B (SE) 0.68 (0.08) −1.29 (0.91) −0.05 (0.02) −0.01 (0.00) 0.89 (0.82)
(CI) (0.52–0.84) (−3.11 to 0.53) (−0.08 to −0.02) (−0.02 to −0.01) (−0.75 to 2.52)
Borderline
ΔR2 0.28** 0.02 0.06** 0.07** 0.03*
β 0.53** −0.13 −0.25** −0.27** 0.19*
B (SE) 0.64 (0.12) −1.59 (1.19) −0.06 (0.02) −0.01 (0.01) 2.27 (1.07)
(CI) (0.41–0.87) (−3.96 to 0.79) (−0.10 to −0.01) (−0.02 to −0.01) (0.14–4.41)
histrionic
ΔR2 0.44** 0.01 0.00 0.00 0.00
β 0.66** −0.10 −0.03 0.04 −0.03
B (SE) 0.58 (0.08) −0.75 (0.67) −0.00 (0.01) 0.00 (0.00) −0.26 (0.70)
(CI) (0.43–0.73) (−2.08 to 0.58) (−0.03 to 0.02) (−0.01 to 0.01) (−1.65 to 1.12)
narcissistic
ΔR2 0.33** 0.00 0.03 0.01 0.00
β 0.58** −0.05 −0.18 0.07 0.07
B (SE) 0.54 (0.09) −0.40 (0.73) −0.03 (0.01) 0.00 (0.00) 0.51 (0.75)
(CI) (0.37–0.71) (−1.85 to 1.04) (−0.05 to 0.00) (−0.00 to 0.01) (−0.99 to 2.01)
avoidant
ΔR2 0.24** 0.01 0.08** 0.02 0.01
β 0.49** −0.11 −0.29** −0.15 0.12
B (SE) 0.58 (0.12) −1.06 (0.95) −0.05 (0.02) −0.01 (0.01) 1.14 (0.88)
(CI) (0.34–0.82) (−2.95 to 0.84) (−0.08 to −0.02) (−0.02 to 0.00) (−0.63 to 2.90)
Dependent
ΔR2 0.35** 0.03 0.09** 0.00 0.01
β 0.59** −0.16 −0.30** −0.05 0.08
B (SE) 0.53 (0.08) −1.39 (0.80) −0.05 (0.01) −0.00 (0.00) 0.65 (0.74)
(CI) (0.36–0.69) (−2.98 to 0.20) (−0.08 to −0.02) (−0.01 to 0.00) (−0.83 to 2.13)
Oc
ΔR2 0.34** 0.04* 0.02 0.00 0.01
β 0.58** −0.19* −0.14 −0.01 0.08
B (SE) 0.67 (0.11) −1.53 (0.73) −0.02 (0.01) 0.00 (0.00) 0.63 (0.72)
(CI) (0.46–0.88) (−2.98 to −0.07) (−0.05 to 0.01) (−0.01 to 0.01) (−0.80 to 2.06)
PD, personality disorder; CAPS, Clinician-Administered PTSD Scale; Tx, treatment; OC, obsessive–compulsive; ΔR2, R-squared change; β, standardized beta; B, unstandardized 
beta; CI, 95% confidence interval for B. All overall F-tests were significant using Holm’s adjusted p-value thresholds (all Fs > 8.47; all ps < 0.001).
For illustrative purposes, only the final variable added to each step is displayed in the table. The dependent variable for each regression was the respective long-term follow-up PD 
feature score. PDs are listed in the first column, as opposed to the top row (which might be more typical) due to space considerations.
*p < 0.05.
**p < 0.01.
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that the co-occurring reductions in PTSD symptom severity 
and these five PDs may be related to more general decreases in 
trait NEM which would be expected to broadly influence the 
expression and severity of these disorders. By contrast, three of 
the four PDs that were not predicted by changes in PTSD sever-
ity (schizoid, histrionic, and narcissistic PD) are most strongly 
FigUre 2 | change in mean raw borderline PD score from baseline to lTFU as a function of improvement in caPs score from baseline to lTFU. 
Degree of improvement on the CAPS was defined by a median split on the baseline minus LTFU difference score (median CAPS change score = 50). The red line 
reflects the average stability for this PD for the sample. CAPS, Clinician-Administered PTSD Scale; PD, personality disorder; LTFU, long-term follow-up. +p < 0.10; 
*p < 0.05; **p < 0.01; ***p < 0.001.
FigUre 1 | change in mean raw antisocial PD score from baseline to lTFU as a function of improvement in caPs score from baseline to lTFU. 
Degree of improvement on the CAPS was defined by a median split on the baseline minus LTFU difference score (median CAPS change score = 50). The red line 
reflects the average stability for this PD for the sample. CAPS, Clinician-Administered PTSD Scale; PD, personality disorder; LTFU, long-term follow-up. +p < 0.10; 
*p < 0.05; **p < 0.01; ***p < 0.001.
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associated with PEM. Though speculative, this may imply that 
reductions in NEM (e.g., perhaps in response to treatment) have 
a greater generalized impact on symptom improvements; while 
by contrast, PEM, which is orthogonal to NEM (37) may be 
unchanged as a function of treatment. Reduced NEM may be a 
mechanism responsible for decreases in both PTSD and the six 
PDs that were associated with PTSD change.
Our results further suggest that the longitudinal stability of 
both antisocial and borderline PD features was attenuated in 
individuals who experienced the greatest amount of PTSD symp-
tom improvement. Interestingly, both of these PDs load strongly 
on the latent dimension of “externalizing” (18). Externalizing 
disorders are associated with impulse control problems (38, 
39). Externalizing PDs are associated with difficulty controlling 
TaBle 4 | hierarchical linear regression analyses predicting change in posttraumatic stress disorder severity as a function of change in PD features.
Predictor
PD step 1 
Baseline caPs
step 2 
Tx completer
step 3 
PD Δ
step 4 
Baseline caPs × PD Δ
step 5 
additional Tx
Paranoid
ΔR2 0.053* 0.036 0.16*** 0.027 0.0020
β 0.23* −0.19 −0.41*** −0.17 −0.041
B (SE) 0.26 (0.13) −8.23 (4.93) −1.71 (0.45) −0.038 (0.024) −1.69 (4.46)
(CI) (0.001–0.51) (−18.06 to 1.59) (−2.60 to −0.82) (−0.086 to 0.010) (−10.59 to 7.22)
schizoida
ΔR2 0.053* 0.036 0.062* 0.018 0.000
β 0.23* −0.19 −0.25* −0.15 0.001
B (SE) 0.26 (0.13) −8.23 (4.93) −1.74 (0.77) −0.056 (0.045) 0.049 (4.74)
(CI) (0.001–0.51) (−18.06 to 1.59) (−3.28 to −0.20) (−0.15 to 0.035) (−9.4 to 9.5)
schizotypal
ΔR2 0.053* 0.036 0.15*** 0.014 0.006
β 0.23* −0.19 −0.40*** −0.14 −0.083
B (SE) 0.26 (0.13) −8.23 (4.93) −1.74 (0.46) −0.028 (0.024) −3.45 (4.64)
(CI) (0.001–0.51) (−18.06 to 1.59) (−2.66 to −0.82) (−0.76 to 0.020) (−12.71 to 5.81)
antisocial
ΔR2 0.053* 0.036 0.13*** 0.005 0.003
β 0.23* −0.19 −0.36*** −0.077 −0.056
B (SE) 0.26 (0.13) −8.23 (4.93) −1.76 (0.53) −0.017 (0.027) −2.32 (4.66)
(CI) (0.001–0.51) (−18.06 to 1.59) (−2.81 to −0.71) (−0.070 to 0.036) (−11.61 to 6.97)
Borderlinea
ΔR2 0.053* 0.036 0.050* 0.016 0.002
β 0.23* −0.19 −0.23* −0.14 −0.043
B (SE) 0.26 (0.13) −8.23 (4.93) −0.88 (0.44) −0.028 (0.025) −1.77 (4.99)
(CI) (0.001–0.51) (−18.06 to 1.59) (−1.75 to −0.009) (−0.078 to 0.022) (−11.73 to 8.18)
histrionica
ΔR2 0.053* 0.036 0.001 0.012 0.000
β 0.23* −0.19 0.027 −0.11 −0.001
B (SE) 0.26 (0.13) −8.23 (4.93) 0.18 (0.79) −0.044 (0.046) −0.044 (4.98)
(CI) (0.001–0.51) (−18.06 to 1.59) (−1.39 to 1.76) (−0.14 to 0.048) (−9.98 to 9.89)
narcissistica
ΔR2 0.053* 0.036 0.027 0.030 0.000
β 0.23* −0.19 −0.16 −0.17 0.011
B (SE) 0.26 (0.13) −8.23 (4.93) −1.01 (0.69) −0.054 (0.035) 0.45 (4.81)
(CI) (0.001–0.51) (−18.06 to 1.59) (−2.39 to 0.37) (−0.13 to 0.016) (−9.16 to 10.05)
avoidant
ΔR2 0.053* 0.036 0.12* 0.027 0.001
β 0.23* −0.19 −0.35* −0.18 −0.039
B (SE) 0.26 (0.13) −8.23 (4.93) −1.72 (0.54) −0.050 (0.032) −1.63 (4.70)
(CI) (0.001–0.51) (−18.06 to 1.59) (−2.80 to −0.65) (−0.11 to 0.014) (−11.00 to 7.74)
Dependenta
ΔR2 0.053* 0.036 0.013 0.057* 0.001
β 0.23* −0.19 −0.13 −0.25* 0.036
B (SE) 0.26 (0.13) −8.23 (4.93) −0.65 (0.64) −0.07 (0.032) 1.50 (4.88)
(CI) (0.001–0.51) (−18.06 to 1.59) (−1.94 to 0.63) (−0.13 to −0.005) (−8.24 to 11.24)
Oc
ΔR2 0.053* 0.036 0.094** 0.065* 0.000
β 0.23* −0.19 −0.32** −0.27* 0.013
B (SE) 0.26 (0.13) −8.23 (4.93) −1.99 (0.70) −0.085 (0.035) 0.53 (4.58)
(CI) (0.001–0.51) (−18.06 to 1.59) (−3.40 to −0.59) (−0.16 to −0.015) (−8.61 to 9.67)
PD, personality disorder; CAPS, Clinician-Administered PTSD Scale; Tx, treatment; OC, obsessive–compulsive; ΔR2, R-squared change; β, standardized beta; B, unstandardized 
beta; CI, 95% confidence interval for B.
For illustrative purposes, only the final variable added to each step is displayed in the table. The dependent variable for each regression was long-term follow-up CAPS score.
aThe overall F-tests for these five analyses were not significant after applying the adjusted Holm p-value threshold; therefore, results of these analyses are not interpreted in the 
manuscript.
*p < 0.05.
**p < 0.001.
***p < 0.001.
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impulses toward aggressive, reckless, and dangerous behavior, 
and this type of behavior may perpetuate stress and lead to 
chronic PTSD symptoms. Given this, our finding that symptoms 
of these two PDs were attenuated in those with PTSD symptom 
reductions highlights the critical importance of treating PTSD 
even in the context of these particularly impairing comorbidities. 
FigUre 3 | change in mean raw caPs score from baseline to lTFU as a function of improvement in Oc PD score from baseline to lTFU. Degree of 
improvement on OC PD was defined by a median split on the baseline minus LTFU difference score (median OC PD change score = 1). OC, obsessive–compulsive; 
CAPS, Clinician-Administered PTSD Scale; PD, personality disorder; LTFU, long-term follow-up. +p < 0.10; *p < 0.05; **p < 0.01; ***p < 0.001.
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Clinicians who view comorbid borderline and antisocial PD as 
contraindications for PTSD treatment may want to consider re-
evaluating this stance.
Our second set of analyses explored how changes in PD 
severity might longitudinally relate to PTSD severity. For these 
analyses, we expected PTSD severity to evidence residualized 
decreases in association with decreases in PD severity, and that 
the longitudinal stability of PTSD severity would be attenuated 
in individuals who experienced the greatest amount of PD symp-
tom improvement. Consistent with predictions, PTSD severity 
at LTFU was associated with changes in five PDs (paranoid, 
schizotypal, antisocial, avoidant, OC PD), at mean levels of 
baseline PTSD severity. Again, because paranoid, schizotypal, 
and antisocial PD are strongly associated with NEM (25), and 
both avoidant and OC PD are equally associated with NEM and 
PEM (25), these findings potentially provide additional support 
to the conjecture that NEM may be a mechanism responsible for 
change in both PTSD and these PDs. Our finding that change in 
OC PD was associated with attenuated longitudinal stability of 
PTSD symptoms is an intriguing one. One possible explanation 
for this may be that reductions in rigidity, a hallmark feature of 
OC PD, may be associated with improved cognitive flexibility, 
which would be expected to aide in the ability to reappraise 
negative trauma-related cognitions. This may be one pathway by 
which changes in this PD relate to residualized changes in PTSD.
The consistent association between change in PTSD and 
change in PDs observed in this study suggests that these two 
sets of disorders may be associated with one another in a more 
fundamental way than originally thought. It is possible that PDs 
may develop out of trauma exposure and PTSD symptoms. For 
example, assault survivors may believe that they are at fault for 
being assaulted and that they are incapable of making good deci-
sions; in turn, they may become dependent upon others to make 
decisions for them and may develop dependent PD. Similarly, 
assault survivors may believe that it is not safe to trust anyone; 
this may develop into paranoid PD. The PD features may there-
fore partially represent trauma-related biases and overgeneral-
ized schemas [sometimes referred to as overaccomodation (20, 
40)], which is targeted in CPT. In this study of women with an 
index rape trauma, a large number had also experienced child-
hood abuse. Such abuse, early in personality development, could 
result in PTSD symptoms, as well as emotions, behaviors, and 
styles of relating to others that become seemingly entrenched 
and characterological. Therefore, trauma may be a risk factor 
linking PTSD and PD comorbidity, which implies that treating 
trauma and associated symptoms may reduce severity of both 
sets of disorders.
Our findings may also be relevant to individuals suffering from 
comorbid PTSD and psychotic symptoms. Traditionally, patients 
with comorbid PTSD and psychosis are not provided trauma-
focused therapy (41, 42) due to the argument that treatment of 
PTSD in patients with psychotic symptoms is contraindicated 
[e.g., Ref. (41)]. Research suggests that schizoid, schizotypal, and 
paranoid PD may all be on the “schizophrenic spectrum” (43) and 
as a result, we were particularly intrigued by evidence in this study 
that change in these PDs was associated with change in PTSD and 
vice versa. Specifically, our results suggested that changes in PTSD 
were associated with both LTFU paranoid and schizotypal PD 
scores, even after controlling for baseline levels of these PDs. This 
implies that PTSD treatment in those with psychotic-spectrum 
disorders [i.e., paranoid, schizotypal, and schizoid PD (27, 28)] is 
not contraindicated, and further, that such treatment may assist 
in reducing symptoms of both disorders. In addition, our finding 
that change in these PDs also affects residualized change in PTSD 
severity, and that individuals who demonstrate larger decreases 
in paranoid and schizoid PD also demonstrate larger decreases in 
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PTSD symptoms, suggests that targeting psychotic-like features 
in therapy may also reduce PTSD symptoms.
Like all studies, the current study was not without limita-
tions. First, the study was limited in that our analyses were based 
on data from only two widely spaced time points (5–10 years 
apart). Therefore, it is unclear whether unmeasured intervening 
factors affected the results, although our follow-up analyses 
further suggest that our results cannot be explained completely 
by additional therapy received after the completion of trauma-
focused therapy. Nevertheless, future studies should replicate 
these analyses with multiple time points, including an earlier 
follow-up, to more fully evaluate the association between PTSD 
and PDs. Second, with only two equally spaced data points, we 
could not fully examine potential reciprocal or bidirectional 
associations in the data or examine if change in PTSD symp-
toms had a greater effect on PDs relative to the effects of change 
in PDs on subsequent PTSD symptoms. For this reason, we 
conducted parallel sets of analyses for PTSD and PDs, but we 
are limited in our ability to draw clear causal inferences. Third, 
this study examined a relatively small number of women who 
had experienced at least one rape (although they were a severely 
traumatized sample). To examine if the results are generalizable 
to other PTSD populations, future investigations should exam-
ine whether men and patients exposed to other kinds of trauma 
demonstrate the same pattern of results. Finally, although we 
included a self-report measure of PDs that has demonstrated 
high construct validity with interview measures in the assess-
ment of PDs, we did not use an interview measure designed to 
diagnose PDs. Future studies should use structured diagnostic 
interviews to assess PDs and determine if results generalize to 
diagnostic threshold-level PDs.
In conclusion, the current study suggests that changes in PTSD 
are associated with changes in a range of PDs, and conversely, 
changes in a number of PDs are associated with changes in PTSD 
symptom severity over time. Our findings raise the possibility of a 
shared underlying mechanism driving the covariation of change: 
NEM. These results have important clinical implications, in that 
they suggest that therapeutic efforts to reduce one set of these 
disorders may impact the symptomotology of the other. This runs 
counter to the common conceptualization that PDs are intrac-
table and that they are contraindications for trauma-focused 
PTSD treatment. Thus, results provide confidence that even 
severe psychopathology and comorbidity may be meaningfully 
ameliorated, thereby reducing the considerable personal, societal, 
and financial burden of these disorders. Because there are short, 
evidence-based protocols for PTSD available, this may be the best 
place to start.
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